Drug Trial Radar · NCT06138613
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness
Last checked: Nov 19, 2026Latest source record: Apr 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
705
Actual
Start
Feb 27, 2023
Primary completion
Sep 30, 2027
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- Vanda PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Nov 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open label study to investigate the safety and efficacy of tradipitant in participants affected by motion sickness during travel
Conditions
- Motion Sickness
Interventions
TradipitantDrug
Oral Capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of tradipitant as measured by reporting of adverse events (AEs).Time frame: through study completion, approximately 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Santa Monica Clinical Trials
Santa Monica, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.